In a study from the University of Hong Kong, scientists found that sodium-glucose cotransporter 2 inhibitors (SGLT2i), the newest drug for lowering blood sugar in type 2 diabetes, could reduce the risks of renal and respiratory diseases.
These diseases include end-stage renal disease (ESRD), obstructive airway disease (OAD) and pneumonia.
These studies provided novel real-world evidence that the diabetes drug may be a better alternative to an older class of glucose-lowering drugs, dipeptidyl peptidase-4 inhibitors (DPP4i) in protecting people with type 2 diabetes.
SGLT2i are a new class of second-line glucose-lowering drugs for type 2 diabetes.
Recent studies have shown that besides glycemic control, SGLT2i also confer heart and renal protection in patients with type 2 diabetes over the past few years.
However, it is not clear whether SGLT2i could provide better cardiorenal protection when compared to individual classes of older glucose-lowering drugs that have been widely prescribed in recent years, such as DPP4i.
In the study, the team examined the association of SGLT2i with kidney and lung health.
They used data from more than 30,000 patients with type 2 diabetes in Hong Kong.
The team found that compared to DPP4i, SGLT2i was strongly linked to lower risks of several kidney diseases.
These findings agreed with the results from previous research and provided real-world evidence suggesting that SGLT2i could offer additional kidney protective effects.
The team also found SGLT2i were strongly linked to strongly reduced risks of several lung diseases.
The team suggests that clinical trials should be carried out for the examination of these respiratory outcomes.
All in all, SGLT2i could be a better alternative drug to DPP4i for people with type 2 diabetes.
If you care about kidney health, please read studies about drug that prevents kidney failure in diabetes, and drinking coffee could help reduce risk of kidney injury.
For more information about health, please see recent studies about foods that may prevent recurrence of kidney stones, and why Viagra may be useful in treating lung diseases.
The study was conducted by Dr. Cheung Ching-lung et al and published in The Journal of Clinical Endocrinology & Metabolism and JAMA Network Open.
Copyright © 2023 Knowridge Science Report. All rights reserved.
